retatrutide phase 2 obesity nejm 2023 jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 4 retatrutide myths debunked by
Description
The applicability of these agents for primary prevention in non-obese individuals without diabetes is also an important evidence gap
Remedy Meds is available in all states but Louisiana
Our website services, content, and products are for informational purposes only
Fun fact: people in larger bodies often have significant muscle mass - it's needed to carry their body weight
Both the pill and injectable versions of Wegovy contain semaglutide, the active GLP-1 receptor agonist that helps regulate appetite, insulin signaling, and metabolic function
